AzTrials
AzTrials

Preterm BirthPhase 4ALECNCT05132829

Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial

A Phase 4 study testing Azithromycin 1 gram IV and Cefazolin and indomethacin in people with Preterm Birth and Obstetric Labor, Premature, run by Thomas Jefferson University at 2 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Azithromycin is an antibiotic that is effective against bacteria that been associated with preterm birth (PTB). The purpose of this study is to evaluate if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. A cerclage is a suture placed in the cervix to prolong gestation. Read more about this study

Who is it for?
Ages 18 to 80 years, women onlyHealthy volunteers can take part
What is being tested?
Azithromycin 1 gram IV and Cefazolin and indomethacin
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
2 sitesUnited States
Study dates
20 Dec 2021to Jun 2025
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Pregnant women with singleton pregnancies
  • ≥18 years old
  • Estimated gestational age less than 24 weeks
  • Meet criteria for an exam indicated cerclage
  • Patients must also be able to provide consent, demonstrate an understanding of the purpose of the study, and agree to the study protocol.

Who cannot join

  • Human immunodeficiency virus (HIV) positive status
  • Known prolonged QT syndrome
  • Major fetal congenital anomalies
  • Temperature of 100.4 F or higher
  • Prior cerclage during the current pregnancy
  • Contraindication to indomethacin
  • Allergy to both penicillin and clindamycin
  • Received indomethacin or any antibiotics within 7 days before their presentation

Trial locations and contacts

2 sites in 1 country.

Rupsa Boelig, MD contact

2159555000

Rupsa.boelig@jefferson.edu

United States2 sites, 2 recruiting
  • Northwestern University

    Chicago, Illinois, 60611

    Emily Miller, MD

    Recruiting
  • Rutgers Robert Wood Johnson

    New Brunswick, New Jersey, 08901

    Justin Brandt, MD

    Recruiting

Other trials in United States

About this study

Official title: Azithromycin to Improve Latency in Exam Indicated Cerclage: a Randomized Control Trial

Azithromycin is an antibiotic that is effective against bacteria that been associated with preterm birth (PTB). The purpose of this study is to evaluate if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. A cerclage is a suture placed in the cervix to prolong gestation.

Read the detailed description

Preterm birth (PTB) continues to be a leading cause of neonatal morbidity and mortality. The rate of spontaneous PTB (delivery before 37 weeks gestation) is one in ten pregnancies and a history of prior preterm birth remains a risk factor for recurrence. The pathophysiology of cervical insufficiency leading to PTB remains poorly understood.

While interventions for PTB prevention are limited, the American College of Obstetrics and Gynecology (ACOG) supports the use of cervical cerclage. A physical exam indicated cerclage may be placed in the setting of painless cervical dilation in the second trimester. The cerclage is believed to provide mechanical support to a weakened cervix and promote the cervical mucosal plug as a barrier to ascending infection.

While many aspects of cerclage use have been extensively studied, the use of antibiotics prior to placement remains under evaluated. While antibiotic use is recommended during cesarean section, preterm premature rupture of membranes (PPROM), and obstetric anal sphincter injuries (OASIS), ACOG currently does not recommend perioperative antibiotics or prophylactic tocolytics at the time of cerclage placement citing insufficient evidence.

Miller et al. performed a randomized controlled trial (RCT) showing an increased incidence of pregnancy prolongation by at least 28 days among women who received indomethacin and perioperative antibiotics in the setting of an exam indicated cerclage compared to those who received no perioperative medications (92.3% vs 62.5%, p=0.01). Participants in the experimental arm received cefazolin or clindamycin if they had a penicillin allergy. Cefazolin is a first generation cephalosporin that has activity against gram positive cocci and gram negative rods and is commonly used for surgical prophylaxis. Clindamycin is a protein synthesis inhibitor and covers gram positive organisms and anaerobic bacteria, making it an appropriate alternative in cases of penicillin allergy. The use of cefazolin specifically with indomethacin has been studied retrospectively and showed a significant improvement in gestational latency (adjusted relative risk [aRR] 1.21, 95% CI 1.05-1.40) and birth weight (+489.8 grams, 95% CI 64.6-915.0).

The use of prolonged azithromycin with cerclage has been studied in a prospective, non- randomized fashion. In this study, patients were given 500mg azithromycin for 3 days and this was repeated every 10 days until 34 weeks. Patients who received this regimen and a cerclage had lower PTB (65.7% vs 5.7%, p<0.001) and reduced immediate fetal mortality (37.1% vs 0%, p<0.001).

The aim of our study is to determine if the addition of azithromycin prior to exam indicated cerclage prolongs gestation. Azithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome and inhibits transpeptidation. It is effective against a wide variety of bacteria, specifically mycoplasma which has been associated with preterm birth. Azithromycin is currently used in obstetrics for patients undergoing nonelective cesarean delivery and as part of latency antibiotics in the setting of PPROM.

Being tested
Azithromycin 1 gram IV, Cefazolin and indomethacin
Keywords
cerclage, preterm birth, premature cervical dilation, antibiotics
Medical subject headings
Premature Birth, Obstetric Labor, Premature, Obstetric Labor Complications, Pregnancy Complications, Uterine Cervical Incompetence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Azithromycin 1 gram IVDrug

    Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.

  • Cefazolin and indomethacinDrug

    Perioperative standard of care with cefazolin and indomethacin

Study groups in NCT05132829
Study groupRoleWhat they receive
Cefazolin and IndomethacinOtherControl arm- perioperative cefazolin and indomethacin
Receives: Drug: Cefazolin and indomethacin
Azithromycin + controlExperimentalperioperative azithromycin, cefazolin and indomethacin
Receives: Drug: Azithromycin 1 gram IV; Drug: Cefazolin and indomethacin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gestational Latency Achieved Between Cerclage Placement and Time of Delivery

    Mean gestational latency achieved Between Cerclage Placement and Time of Delivery

    Measured: 24 weeks following cerclage placement

Secondary outcomes (7)
  1. Preterm birth <37 weeks, <34 weeks, <32 weeks, <28 weeks, <24 weeks

    Preterm delivery stratified by gestational age at delivery in weeks

    Measured: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.

  2. Mean gestational age at delivery

    Measured in weeks

    Measured: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.

  3. chorioamnionitis

    Histologic or clinical diagnosis

    Measured: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.

  4. birth weight

    measured in grams

    Measured: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.

  5. Admission to neonatal intensive care unit

    If admitted, measured in days

    Measured: at delivery following cerclage placement. Latest will occur 26 weeks following cerclage placement.

  6. Neonatal Morbidity and Mortality

    including apgars, Respiratory Distress Syndrome, Bronchopulmonary dysplasia, Retinopathy of prematurity, Intraventricular hemorrhage (IVH) (grade 3 or 4), patent ductus arteriosus, and neonatal death

    Measured: within 28 days of delivery

  7. Cervicovaginal cytokine analysis

    Measurement of proinflammatory cytokines in pg/ml (IL-1B, IL-2, IL-4, IL-6, IL-8, IL-8, IL-10, G-CSF, GM-CSF, MCP-1, TNF-a, IFN-g, CCL5, VEGF, ICAM-1) from cervicovaginal fluid at the time of cerclage placement and at follow up 1-4 weeks after placement

    Measured: Cerclage placement and 1-4 weeks after

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Nov 2021
  2. Study start20 Dec 2021
  3. Primary completionDec 2024 (estimated)
  4. Study completionJun 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05132829
Sponsor's protocol ID
21D.746
Acronym
ALEC
Status last verified
Jun 2023
First submitted
25 Oct 2021
Last updated
26 Jun 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Jayakumaran JS, Khanuja K, Fischer SA, Miller ES, Rosenfeld EB, Brandt JS, Piacquadio M, Kalifeh A, Boelig RC. Azithromycin to improve latency in examination-indicated cerclage: a multicenter randomized controlled trial. Am J Obstet Gynecol MFM. 2026 Apr;8(4):101818. doi: 10.1016/j.ajogmf.2025.101818. Epub 2025 Oct 22.

    PubMed 41135925

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Azithromycin 1 gram IV and Cefazolin and indomethacin in people with Preterm Birth and Obstetric Labor, Premature, run by Thomas Jefferson University at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Rupsa Boelig, MD (2159555000, Rupsa.boelig@jefferson.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gestational Latency Achieved Between Cerclage Placement and Time of Delivery (time frame: 24 weeks following cerclage placement). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05132829, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in